← Search another drug
PatientPulse · by PatientPartner
Tecfidera dimethyl fumarate
High confidence
~60 public patient conversations and reviews referenced (blogs, MS society forums, MSAA community, review sites)
Executive intelligence
The signal that moves starts & adherence
42%Positive sentiment in discussion
122,024FDA adverse-event reports
33%Flagged serious
79%Reports name female patients
The single biggest commercial risk is not initial side effects but the generic-switch wave triggering renewed flushing and acid reflux in long-stable patients, eroding brand loyalty and driving upstream queries about Vumerity and Kesimpta.
- Early GI and flushing side effects dominate the first 1-3 months and are the primary driver of discontinuation, yet most patients who survive this window report durable relapse suppression for years.
- The generic dimethyl fumarate switch is generating a new wave of acid reflux and intensified flushing complaints from previously stable brand-Tecfidera users, creating a near-term retention crisis.
- Insurance cost barriers and Medicare Part D co-pay assistance exclusions leave a meaningful segment of patients unable to afford treatment, representing a documented access and adherence failure point.
- PML and lymphopenia anxiety are ever-present psychological weights, especially for JC-positive patients, and unresolved fear around these risks pushes patients toward higher-efficacy alternatives like Kesimpta.